EP0872552A1
(en)
*
|
1997-04-15 |
1998-10-21 |
Leadd B.V. |
A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
|
NL9101680A
(nl)
|
1991-10-04 |
1993-05-03 |
Tno |
Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
US6080569A
(en)
*
|
1993-06-24 |
2000-06-27 |
Merck & Co., Inc. |
Adenovirus vectors generated from helper viruses and helper-dependent vectors
|
DE69533295T3
(de)
*
|
1994-02-16 |
2009-07-16 |
The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services |
Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
DE69531387T2
(de)
|
1994-08-16 |
2004-04-22 |
Crucell Holland B.V. |
Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
|
US5998205A
(en)
*
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
PT1445322E
(pt)
|
1995-06-15 |
2010-01-19 |
Crucell Holland Bv |
Sistemas de empacotamento para adenovírus recombinante humano destinados a terapia genética
|
US6265212B1
(en)
*
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
US6261554B1
(en)
|
1995-07-25 |
2001-07-17 |
Introgene B.V. |
Compositions for targeted gene delivery
|
WO1997020943A1
(en)
*
|
1995-12-01 |
1997-06-12 |
Introgene B.V. |
Regulated protein expression in stably transfected mammalian cells
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
US6110744A
(en)
|
1996-11-13 |
2000-08-29 |
Board Of Regents, The University Of Texas System |
Diminishing viral gene expression by promoter replacement
|
AU5070298A
(en)
|
1996-12-05 |
1998-06-29 |
Introgene B.V. |
Genetic modification of primate hemopoietic repopulating stem cells
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
WO1998039411A1
(en)
|
1997-03-04 |
1998-09-11 |
Baxter International Inc. |
Adenovirus e1-complementing cell lines
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
FR2774699B1
(fr)
*
|
1997-11-17 |
2003-10-03 |
Rhone Poulenc Rorer Sa |
Methode de reduction des evenements de recombinaison homologue
|
AU1536999A
(en)
*
|
1997-11-26 |
1999-06-15 |
Board Of Regents, The University Of Texas System |
Modified sv40 viral vectors
|
WO1999032647A1
(en)
*
|
1997-12-23 |
1999-07-01 |
Introgene B.V. |
Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
|
CA2319112C
(en)
|
1998-02-13 |
2003-10-28 |
Genetrace Systems, Inc. |
Use of ribozymes for functionating genes
|
US5981225A
(en)
*
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6670188B1
(en)
*
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0959136A1
(en)
|
1998-05-20 |
1999-11-24 |
Introgene B.V. |
Targeted delivery through a cationic amino acid transporter
|
US6413776B1
(en)
*
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US6900049B2
(en)
*
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
CA2348838A1
(en)
*
|
1998-10-27 |
2000-05-04 |
Crucell Holland B.V. |
Improved aav vector production
|
IT1302403B1
(it)
*
|
1998-11-06 |
2000-09-05 |
Angeletti P Ist Richerche Bio |
Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
IL133032A
(en)
*
|
1998-11-20 |
2007-06-03 |
Introgene Bv |
Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
|
EP1016726A1
(en)
*
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gene therapy to promote angiogenesis
|
AU776067B2
(en)
*
|
1999-03-04 |
2004-08-26 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
US6869936B1
(en)
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
CN100457914C
(zh)
*
|
1999-04-15 |
2009-02-04 |
荷兰克鲁塞尔公司 |
用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US20060099685A1
(en)
*
|
1999-04-15 |
2006-05-11 |
Yallop Christopher A |
Recombinant expression of factor VIII in human cells
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
AU4437100A
(en)
*
|
1999-04-23 |
2001-02-13 |
Crucell Holland B.V. |
Means and methods for nucleic acid transfer
|
ES2372823T3
(es)
|
1999-05-17 |
2012-01-26 |
Crucell Holland B.V. |
Adenovirus recombinante del serotipo ad11.
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
EP1200622A4
(en)
|
1999-07-06 |
2004-12-22 |
Merck & Co Inc |
HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS
|
EP1067190A1
(en)
*
|
1999-07-09 |
2001-01-10 |
Introgene B.V. |
Gene therapy for enhancing and/or inducing angiogenesis
|
EP1083228A1
(en)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Modified adenoviral vectors for use in gene therapy
|
AU7560500A
(en)
*
|
1999-09-10 |
2001-04-17 |
Crucell Holland B.V. |
Modified adenoviral vectors for use in gene therapy
|
EP1083229A1
(en)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Modified adenoviral vectors for use in gene therapy
|
US6365394B1
(en)
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
US7115391B1
(en)
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
DE19955558C2
(de)
*
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
JP2003516743A
(ja)
*
|
1999-12-14 |
2003-05-20 |
ジェノボ, インコーポレイテッド |
複製不能アデノウイルスの製造のための方法および組成物
|
CA2396779A1
(en)
*
|
2000-01-07 |
2001-07-12 |
Stichting Klinishce Farmacologie Groningen |
Gene therapy to promote angiogenesis and/or the treatment of heart failure
|
US7132277B1
(en)
|
2000-01-31 |
2006-11-07 |
Merck & Co., Inc. |
Helper dependent vector system for gene therapy
|
CA2404085A1
(en)
*
|
2000-03-24 |
2001-10-04 |
Cell Genesys, Inc. |
Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising uroplakin-specific transcriptional regulatory sequences, and methods of use thereof
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
KR20010064682A
(ko)
*
|
2000-07-01 |
2001-07-11 |
김재호 |
E1b가 감쇠된 아데노바이러스를 이용한 cd/5-fc및 hsv-1 tk/gcv의 이중 자멸 유전자 시스템
|
US20020164333A1
(en)
*
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
US7223406B2
(en)
*
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US6852323B2
(en)
|
2000-07-21 |
2005-02-08 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US6984522B2
(en)
*
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6733993B2
(en)
*
|
2000-09-15 |
2004-05-11 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
|
US20040101957A1
(en)
*
|
2001-09-14 |
2004-05-27 |
Emini Emilio A. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
|
EP1322774A2
(en)
*
|
2000-09-20 |
2003-07-02 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for dendritic cells
|
DE60138403D1
(de)
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
US6573092B1
(en)
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
WO2002068627A2
(en)
*
|
2001-02-23 |
2002-09-06 |
Novartis Ag |
Vector constucts
|
JP2004533815A
(ja)
|
2001-03-14 |
2004-11-11 |
ミリアド・ジェネティックス・インコーポレイテッド |
Tsg101−gag相互作用およびその使用
|
EP1256803A1
(en)
*
|
2001-05-07 |
2002-11-13 |
Crucell Holland B.V. |
Methods for the identification of antiviral compounds
|
US6682929B2
(en)
|
2001-07-23 |
2004-01-27 |
Genvec, Inc. |
Adenovector complementing cells
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
US20030119771A1
(en)
*
|
2001-08-22 |
2003-06-26 |
Rompaey Luc Van |
Modulators of bone homeostasis identified in a high-throughput screen
|
CN1880457B
(zh)
|
2001-10-11 |
2010-05-26 |
麦克公司 |
Ad6重组核酸
|
US7598362B2
(en)
|
2001-10-11 |
2009-10-06 |
Merck & Co., Inc. |
Hepatitis C virus vaccine
|
ES2381104T3
(es)
|
2001-10-29 |
2012-05-23 |
Crucell Holland B.V. |
Métodos y medios para producir proteínas con modificaciones postraduccionales predeterminadas
|
EP1465987B1
(en)
|
2001-12-07 |
2008-01-23 |
Crucell Holland B.V. |
Production of viruses, viral isolates and vaccines
|
SI1456238T1
(sl)
*
|
2001-12-17 |
2008-08-31 |
Crucell Holland Bv |
Proizvodnja f(ab)2 fragmentov v sesalskih celicah
|
EP1466016A2
(en)
|
2002-01-09 |
2004-10-13 |
Riken Institute Of Physical And Chemical Research |
Cancer profiles
|
WO2003062400A2
(en)
*
|
2002-01-24 |
2003-07-31 |
The Scripps Research Institute |
Fiber shaft modifications for efficient targeting
|
CA2476447A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Merck & Co., Inc. |
Method of determining adenovirus particle concentration
|
JP4354280B2
(ja)
|
2002-03-01 |
2009-10-28 |
イミューノメディクス、インコーポレイテッド |
Rs7抗体
|
DE60319210T2
(de)
*
|
2002-03-29 |
2009-02-12 |
Merck & Co., Inc. |
Verfahren zur virusproduktion
|
WO2003087348A1
(en)
*
|
2002-04-08 |
2003-10-23 |
The Johns Hopkins University |
Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
|
DE60329835D1
(de)
*
|
2002-04-25 |
2009-12-10 |
Crucell Holland Bv |
Mittel und verfahren zur herstellung von adenovirusvektoren
|
NZ534865A
(en)
*
|
2002-04-25 |
2008-07-31 |
Crucell Holland Bv |
Stable adenoviral vectors and methods for propagation thereof
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
BR0311799A
(pt)
|
2002-06-14 |
2005-05-10 |
Immunomedics Inc |
Anticorpo monoclonal hpam4
|
US7226755B1
(en)
*
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
US7507568B2
(en)
*
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
AU2003288273A1
(en)
|
2002-10-23 |
2004-05-13 |
Crucell Holland B.V. |
New settings for recombinant adenoviral-based vaccines
|
US20080153083A1
(en)
*
|
2003-10-23 |
2008-06-26 |
Crucell Holland B.V. |
Settings for recombinant adenoviral-based vaccines
|
US20050221493A1
(en)
*
|
2002-12-04 |
2005-10-06 |
Crucell Holland B.V. |
Recombinant virus production for the manufacturing of vaccines
|
WO2004055187A1
(en)
|
2002-12-17 |
2004-07-01 |
Crucell Holland B.V. |
Recombinant viral-based malaria vaccines
|
WO2004056986A2
(en)
*
|
2002-12-20 |
2004-07-08 |
Chromagenics B.V. |
Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
|
EP2181704B1
(en)
|
2002-12-30 |
2015-05-06 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
US20070275915A1
(en)
*
|
2003-04-15 |
2007-11-29 |
Cell Genesys, Inc. |
Tmprss2 Regulatory Sequences and Uses Thereof
|
WO2004092396A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Novartis Ag |
Flap endonuclease 1 (fen1) regulatory sequences and uses thereof
|
CA2520891C
(en)
*
|
2003-05-09 |
2014-07-08 |
Crucell Holland B.V. |
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
|
WO2004104046A1
(en)
*
|
2003-05-23 |
2004-12-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
US7498024B2
(en)
*
|
2003-06-03 |
2009-03-03 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
EP1639090A4
(en)
|
2003-06-09 |
2008-04-16 |
Univ Michigan |
COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
US7026164B2
(en)
*
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
US20050186178A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Ennist David L. |
Oncolytic adenoviral vectors encoding GM-CSF
|
JP4749334B2
(ja)
*
|
2003-10-02 |
2011-08-17 |
クルセル ホランド ベー ヴェー |
組換えアデノウイルス用パッケージング細胞
|
US7482156B2
(en)
*
|
2003-10-15 |
2009-01-27 |
Cell Genesys, Inc. |
Hepatocellular carcinoma specific promoter and uses thereof
|
EP1528101A1
(en)
*
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
EP1687032B1
(en)
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
|
CA2993042A1
(en)
|
2004-01-23 |
2005-08-04 |
Msd Italia S.R.L. |
Chimpanzee adenovirus vaccine carriers
|
CA2554779A1
(en)
*
|
2004-02-03 |
2005-08-18 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
ES2329607T3
(es)
*
|
2004-02-23 |
2009-11-27 |
Crucell Holland B.V. |
Metodos de purificacion de virus.
|
US7473418B2
(en)
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
EP1737885A2
(en)
|
2004-04-12 |
2007-01-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Method of using adenoviral vectors to induce an immune response
|
JP2008505853A
(ja)
*
|
2004-04-13 |
2008-02-28 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
|
US7964196B2
(en)
*
|
2004-05-25 |
2011-06-21 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
US20060062764A1
(en)
*
|
2004-08-25 |
2006-03-23 |
Seshidar-Reddy Police |
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
EP1784493A2
(en)
*
|
2004-09-01 |
2007-05-16 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
ATE470454T1
(de)
|
2004-09-13 |
2010-06-15 |
Genzyme Corp |
Multimere konstrukte
|
PL2572661T3
(pl)
|
2004-10-05 |
2020-06-01 |
Genzyme Corporation |
Stopniowana kaniula
|
CA2582353A1
(en)
|
2004-10-06 |
2006-04-20 |
University Of Rochester |
Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
|
CN101203530A
(zh)
*
|
2004-10-28 |
2008-06-18 |
匹兹堡大学高等教育联邦体系 |
关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗
|
US8999667B2
(en)
*
|
2004-11-08 |
2015-04-07 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
SI1809750T1
(sl)
|
2004-11-08 |
2012-08-31 |
Chromagenics Bv |
Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
|
BRPI0517380A
(pt)
*
|
2004-11-08 |
2008-10-07 |
Chromagenics Bv |
molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
|
US8039230B2
(en)
*
|
2004-11-08 |
2011-10-18 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US20060195935A1
(en)
|
2004-11-08 |
2006-08-31 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
WO2006065827A2
(en)
*
|
2004-12-13 |
2006-06-22 |
Canji, Inc. |
Cell lines for production of replication-defective adenovirus
|
EP2110667A1
(en)
|
2005-01-20 |
2009-10-21 |
University Of Rochester |
Thoredoxin interacting protein (TXNIP) as regulator of vascular function
|
JP2008538894A
(ja)
*
|
2005-02-11 |
2008-11-13 |
メルク エンド カムパニー インコーポレーテッド |
アデノウイルス血清型26ベクター、核酸およびそれにより製造されたウイルス
|
DK1869171T4
(da)
*
|
2005-04-11 |
2016-01-18 |
Crucell Holland Bv |
Virusrensning under anvendelse af ultrafiltrering
|
US20060234347A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Harding Thomas C |
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
|
EP1885863B1
(en)
|
2005-05-31 |
2014-11-19 |
The Regents of the University of Colorado, a body corporate |
Methods for delivering genes
|
US20070105133A1
(en)
*
|
2005-06-13 |
2007-05-10 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
WO2006135886A2
(en)
*
|
2005-06-13 |
2006-12-21 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
EP2570423B1
(en)
|
2005-06-17 |
2023-05-03 |
MSD Italia S.r.l. |
Hepatitis C virus nucleic acid vaccine
|
EP1907536B1
(en)
*
|
2005-07-22 |
2010-04-07 |
Crucell Holland B.V. |
Cell line for producing coronaviruses
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
CA2620495A1
(en)
*
|
2005-08-31 |
2007-03-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
DE06814528T1
(de)
|
2005-09-12 |
2012-01-05 |
The Regent Of The University Of Michigan |
Wiederkehrende genfusionen bei prostatakrebs
|
US8652467B2
(en)
*
|
2005-10-14 |
2014-02-18 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
EP2500360B1
(en)
|
2005-10-31 |
2015-08-05 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
EP1945754B1
(en)
*
|
2005-10-31 |
2014-07-23 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
BRPI0618441B8
(pt)
|
2005-11-10 |
2021-07-27 |
Genvec Inc |
vetor adenoviral
|
DE602006019916D1
(de)
*
|
2005-12-12 |
2011-03-10 |
Canji Inc |
Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
JP2009526066A
(ja)
|
2006-02-09 |
2009-07-16 |
ジェンザイム・コーポレーション |
遅速性脳室内送達
|
WO2008121102A2
(en)
*
|
2006-02-21 |
2008-10-09 |
The Regents Of The University Of Michigan |
Hedgehog signaling pathway antagonist cancer treatment
|
US7968700B2
(en)
*
|
2006-03-20 |
2011-06-28 |
Chromagenics B.V. |
Expression augmenting DNA fragments, use thereof, and methods for finding thereof
|
DE602007005366D1
(de)
*
|
2006-04-07 |
2010-04-29 |
Chimeros Inc |
Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
|
EP2371865B1
(en)
|
2006-04-07 |
2017-07-12 |
Aerpio Therapeutics, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
|
EP2041311A4
(en)
|
2006-06-23 |
2010-07-07 |
Myriad Genetics Inc |
VARIANTS OF THE DPYD GENE AND THEIR USE
|
WO2007149594A2
(en)
*
|
2006-06-23 |
2007-12-27 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
US7622593B2
(en)
*
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
PT2634242T
(pt)
|
2006-07-14 |
2017-07-12 |
Patheon Holdings I B V |
Processo melhorado para cultura de células
|
EP2049151A4
(en)
|
2006-07-17 |
2010-03-24 |
Quintessence Biosciences Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
WO2008030605A2
(en)
*
|
2006-09-08 |
2008-03-13 |
The Regents Of The University Of Michigan |
Herv group ii viruses in lymphoma and cancer
|
US20080248060A1
(en)
*
|
2007-01-09 |
2008-10-09 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US11371194B2
(en)
*
|
2007-01-19 |
2022-06-28 |
Brock Usa, Llc |
Base for turf system
|
US8148147B2
(en)
*
|
2007-01-24 |
2012-04-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
DE602008004476D1
(de)
*
|
2007-03-09 |
2011-02-24 |
Vectorlogics Inc |
Zellen für adenovirusvektor- und proteinherstellung
|
US20090226525A1
(en)
*
|
2007-04-09 |
2009-09-10 |
Chimeros Inc. |
Self-assembling nanoparticle drug delivery system
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US20090324596A1
(en)
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
EP2167689B1
(en)
|
2007-07-06 |
2012-10-31 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
US20090047269A1
(en)
|
2007-08-16 |
2009-02-19 |
The Regents Of The University Of Michigan |
Metabolomic cancer targets
|
DE102007041655A1
(de)
|
2007-09-03 |
2009-03-05 |
Medicyte Gmbh |
Vermehrung von primären Zellen und deren Verwendung
|
US8697062B2
(en)
*
|
2007-10-08 |
2014-04-15 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapeutics
|
TWI488640B
(zh)
|
2008-04-16 |
2015-06-21 |
Ferring Int Ct Sa |
藥學製劑
|
US8193151B2
(en)
*
|
2008-04-25 |
2012-06-05 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
PL2307538T3
(pl)
*
|
2008-07-15 |
2016-03-31 |
Crucell Holland Bv |
Skalowalny proces do hodowania komórek PER.C6 i wytwarzania z nich produktów
|
US8871515B2
(en)
|
2008-09-17 |
2014-10-28 |
Isogenis, Inc. |
Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
|
US7982013B2
(en)
|
2008-09-26 |
2011-07-19 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
US8551789B2
(en)
|
2010-04-01 |
2013-10-08 |
OncoMed Pharmaceuticals |
Frizzled-binding agents and their use in screening for WNT inhibitors
|
EP2334695B1
(en)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
US20110184154A1
(en)
*
|
2008-10-17 |
2011-07-28 |
Percivia Llc |
Cell broth clarification and host cell protein removal
|
ES2532015T3
(es)
*
|
2008-11-03 |
2015-03-23 |
Crucell Holland B.V. |
Método para la producción de vectores adenovíricos
|
WO2010081001A2
(en)
|
2009-01-09 |
2010-07-15 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in cancer
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
SG173065A1
(en)
|
2009-01-20 |
2011-08-29 |
Transgene Sa |
Soluble icam-1 as biomarker for prediction of therapeutic response
|
WO2010107991A2
(en)
|
2009-03-18 |
2010-09-23 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
|
KR20110138354A
(ko)
|
2009-03-24 |
2011-12-27 |
트랜스진 에스.에이. |
환자를 모니터링하기 위한 바이오마커
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
US20120058493A1
(en)
|
2009-04-17 |
2012-03-08 |
Bruce Acres |
Biomarker for monitoring patients
|
CN102439037B
(zh)
|
2009-04-23 |
2015-01-07 |
克鲁塞尔荷兰公司 |
重组人α1-抗胰蛋白酶
|
EP4218794A3
(en)
|
2009-06-10 |
2023-09-13 |
New York University |
Immunological targeting of pathological tau proteins
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
MX2011007420A
(es)
|
2009-07-06 |
2011-12-14 |
Akebia Therapeutics Inc |
Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
|
EP2451935A2
(en)
|
2009-07-08 |
2012-05-16 |
Glycotope GmbH |
Perfusion bioreactor
|
HUE028240T2
(en)
|
2009-07-10 |
2016-12-28 |
Transgene Sa |
Biomarker Patient Selection and Related Procedures
|
KR101548790B1
(ko)
|
2009-07-16 |
2015-08-31 |
크루셀 홀란드 비.브이. |
백신 제조를 위한 고역가 폴리오바이러스의 제조
|
KR20120052352A
(ko)
|
2009-08-07 |
2012-05-23 |
트랜스진 에스.에이. |
Hbv 감염을 치료하는 조성물
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
MX2012004222A
(es)
*
|
2009-10-15 |
2012-06-08 |
Crucell Holland Bv |
Metodo para purificacion de particulas de adenovirus.
|
ES2445713T3
(es)
|
2009-10-15 |
2014-03-04 |
Crucell Holland B.V. |
Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
EP2498791B1
(en)
|
2009-11-09 |
2014-12-24 |
GenVec, Inc. |
Methods of propagating monkey adenoviral vectors
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
JP5960606B2
(ja)
|
2010-01-08 |
2016-08-02 |
プロフィブリックス ビーブイ |
伸長α鎖を有するフィブリノーゲンが濃縮されたフィブリノーゲン調製物
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
WO2011098592A1
(en)
|
2010-02-15 |
2011-08-18 |
Crucell Holland B.V. |
Method for the production of ad26 adenoviral vectors
|
US9682133B2
(en)
|
2010-03-17 |
2017-06-20 |
Cornell University |
Disrupted adenovirus-based vaccine against drugs of abuse
|
EP2548025A4
(en)
|
2010-03-17 |
2013-09-25 |
Univ Michigan |
USE OF PHOTOEPITOPES FOR PROFILING AN IMMUNE REACTION
|
CN103038343A
(zh)
|
2010-03-23 |
2013-04-10 |
英特瑞克斯顿股份有限公司 |
条件表达治疗蛋白的载体,包含所述载体的宿主细胞,及其应用
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
CN103118702A
(zh)
|
2010-09-20 |
2013-05-22 |
克鲁塞尔荷兰公司 |
活动性结核病的治疗性接种
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
DE102010041958A1
(de)
|
2010-10-04 |
2012-04-05 |
Medicyte Gmbh |
Geeignete Hepatozyten für in-vitro Genotoxitätstests
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
EP2654786B1
(en)
|
2010-12-20 |
2019-02-20 |
GenVec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
US20130344053A1
(en)
|
2010-12-28 |
2013-12-26 |
University Of Rochester |
Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides
|
EP2670426B1
(en)
|
2011-01-31 |
2017-05-10 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
WO2012122025A2
(en)
|
2011-03-04 |
2012-09-13 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
ES2592628T3
(es)
|
2011-07-06 |
2016-11-30 |
Sykehuset Sorlandet Hf |
Terapia dirigida al receptor del factor de crecimiento epidérmico (EGFR)
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Hbv聚合酶突變體
|
HUE051021T2
(hu)
|
2011-09-07 |
2021-01-28 |
Sinai School Medicine |
Ceramidáz és sejtek differenciálódása
|
US8865188B2
(en)
|
2011-09-09 |
2014-10-21 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
TW201321016A
(zh)
|
2011-09-29 |
2013-06-01 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(二)
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
CN107937440A
(zh)
|
2011-10-05 |
2018-04-20 |
金维克有限公司 |
猴腺病毒(大猩猩)或腺病毒载体及其使用方法
|
US9580476B2
(en)
|
2011-10-05 |
2017-02-28 |
Genvec, Inc. |
Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
|
CA2851251C
(en)
|
2011-10-05 |
2023-09-12 |
Genvec, Inc. |
Simian (gorilla) adenovirus or adenoviral vectors and methods of use
|
JP6757119B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
WO2013077645A1
(ko)
|
2011-11-24 |
2013-05-30 |
주식회사 바이로메드 |
아데노바이러스 생산 신규 세포주 및 그의 용도
|
US20150004144A1
(en)
|
2011-12-02 |
2015-01-01 |
The General Hospital Corporation |
Differentiation into brown adipocytes
|
ES2623259T3
(es)
|
2011-12-08 |
2017-07-10 |
Virovek, Inc. |
Vectores que albergan genes tóxicos, métodos y usos de los mismos
|
EP2809346A1
(en)
|
2012-02-02 |
2014-12-10 |
GenVec, Inc. |
Adenoviral vector-based malaria vaccine
|
MX367842B
(es)
|
2012-02-07 |
2019-09-09 |
Global Bio Therapeutics Inc |
Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo.
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
NZ628385A
(en)
|
2012-03-12 |
2016-09-30 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
AP2014007994A0
(en)
|
2012-03-22 |
2014-10-31 |
Crucell Holland Bv |
Vaccine against rsv
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
US9790519B2
(en)
|
2012-05-29 |
2017-10-17 |
Genvec, Inc. |
Modified serotype 28 adenoviral vectors
|
WO2013180967A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
MX366206B
(es)
|
2012-07-10 |
2019-07-02 |
Transgene Sa |
Vacuna de antígeno micobacteriano.
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
SG11201500508XA
(en)
|
2012-08-03 |
2015-02-27 |
Sanofi Pasteur |
Production of infectious influenza viruses
|
EP2890720B1
(en)
|
2012-08-30 |
2019-07-17 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
US9694050B2
(en)
|
2012-10-21 |
2017-07-04 |
University Of Rochester |
THY1 (CD90) as a novel therapy to control adipose tissue accumulation
|
WO2014066328A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
SG11201503864TA
(en)
|
2012-11-16 |
2015-06-29 |
Beth Israel Hospital |
Recombinant adenoviruses and use thereof
|
US20150320861A1
(en)
|
2012-12-21 |
2015-11-12 |
Sykehuset Sørlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
CN105073195A
(zh)
|
2013-02-04 |
2015-11-18 |
昂科梅德制药有限公司 |
使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
KR101606910B1
(ko)
|
2013-03-29 |
2016-04-04 |
충북보건과학대학교 산학협력단 |
아데노바이러스 벡터 생산용 a549 기반 세포주
|
EP3741385A1
(en)
|
2013-04-17 |
2020-11-25 |
Genzyme Corporation |
Compositions for use in a method of treating and preventing macular degeneration
|
US9822418B2
(en)
|
2013-04-22 |
2017-11-21 |
Icahn School Of Medicine At Mount Sinai |
Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
|
CN110590916A
(zh)
|
2013-04-25 |
2019-12-20 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
US9988617B2
(en)
|
2013-05-21 |
2018-06-05 |
President And Fellows Of Harvard College |
Engineered heme-binding compositions and uses thereof
|
MY171210A
(en)
|
2013-06-17 |
2019-10-02 |
Janssen Vaccines & Prevention Bv |
Stabilized soluble pre-fusion rsv f polypeptides
|
ES2525768B1
(es)
*
|
2013-06-24 |
2015-10-07 |
Curaxis, S.L. |
Procedimiento para la producción de proteínas recombinantes glicosiladas.
|
EP3030163B1
(en)
|
2013-08-08 |
2019-03-20 |
Global Bio Therapeutics, Inc. |
Clamp device for minimally invasive procedures
|
SI3046536T1
(sl)
|
2013-09-19 |
2019-05-31 |
Janssen Vaccines & Prevention B.V. |
Izboljšane formulacije adenovirusa
|
CA2924042C
(en)
|
2013-09-30 |
2023-04-18 |
Crucell Holland B.V. |
Method for the clarification of high density crude cell culture harvest
|
US10765731B2
(en)
|
2014-01-09 |
2020-09-08 |
Transgene Sa |
Fusion of heterooligomeric mycobacterial antigens
|
JP6719381B2
(ja)
|
2014-02-06 |
2020-07-08 |
ジェンザイム・コーポレーション |
黄斑変性を処置し、予防するための組成物および方法
|
EP2927685A1
(en)
|
2014-04-02 |
2015-10-07 |
Medicyte GmbH |
Suitable hepatocytes for in-vitro hepatitis tests
|
KR102364111B1
(ko)
|
2014-07-24 |
2022-02-17 |
얀센 백신스 앤드 프리벤션 비.브이. |
세포 배양물로부터 폴리오바이러스의 정제 방법
|
KR20230053709A
(ko)
|
2014-09-07 |
2023-04-21 |
셀렉타 바이오사이언시즈, 인크. |
항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
|
WO2016044707A1
(en)
|
2014-09-18 |
2016-03-24 |
Cedars-Sinai Medical Center |
Compositions and methods for treating fibrosis
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
CN107075521B
(zh)
|
2014-11-04 |
2021-06-08 |
扬森疫苗与预防公司 |
治疗性hpv16疫苗
|
JP6677737B2
(ja)
|
2015-02-19 |
2020-04-08 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
キャピラリーゾーン電気泳動を用いたウイルス粒子の定量方法
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
WO2016146844A1
(en)
|
2015-03-18 |
2016-09-22 |
Janssen Vaccines & Prevention B.V. |
Assays for recombinant expression systems
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
WO2016168601A1
(en)
|
2015-04-17 |
2016-10-20 |
Khalid Shah |
Agents, systems and methods for treating cancer
|
EP4194001A1
(en)
|
2015-04-22 |
2023-06-14 |
Cedars-Sinai Medical Center |
Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity
|
EP3319634B1
(en)
|
2015-07-07 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
IL288541B
(en)
|
2015-07-07 |
2022-08-01 |
Janssen Vaccines Prevention B V |
vaccine against rsv
|
MY195389A
(en)
|
2015-08-20 |
2023-01-18 |
Janssen Vaccines & Prevention Bv |
Therapeutic HPV18 Vaccines
|
WO2017060329A1
(en)
|
2015-10-06 |
2017-04-13 |
Janssen Vaccines & Prevention B.V. |
Methods for preventing plastic-induced degradation of biologicals
|
WO2017074517A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Seracare Life Sciences, Inc. |
Adenovirus control virus
|
WO2017079442A1
(en)
|
2015-11-04 |
2017-05-11 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
KR102401247B1
(ko)
|
2016-04-05 |
2022-05-25 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
MY190320A
(en)
|
2016-04-05 |
2022-04-13 |
Janssen Vaccines & Prevention Bv |
Stabilized soluble pre-fusion rsv f proteins
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
US10517944B2
(en)
|
2016-05-02 |
2019-12-31 |
Janssen Vaccines & Prevention B.V. |
Therapeutic HPV vaccine combinations
|
WO2017191147A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
RU2758238C2
(ru)
|
2016-05-12 |
2021-10-26 |
Янссен Вэксинс Энд Превеншн Б.В. |
Эффективный и сбалансированный двунаправленный промотор
|
EA039124B1
(ru)
|
2016-05-30 |
2021-12-08 |
Янссен Вэксинс Энд Превеншн Б.В. |
Стабилизированные f-белки rsv до слияния
|
CN109312362B
(zh)
|
2016-06-20 |
2022-06-28 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
WO2018013509A1
(en)
|
2016-07-11 |
2018-01-18 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for diagnosing and treating arrhythmias
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Hpvワクチン
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
EP3565572A1
(en)
|
2017-01-07 |
2019-11-13 |
Selecta Biosciences, Inc. |
Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
|
WO2018140630A1
(en)
|
2017-01-25 |
2018-08-02 |
Northwestern University |
Autophagy inducers for treatment of cns conditions
|
NZ755252A
(en)
|
2017-02-09 |
2022-05-27 |
Janssen Vaccines & Prevention Bv |
Potent and short promoter for expression of heterologous genes
|
CA3053304A1
(en)
|
2017-02-17 |
2018-08-23 |
Lonza Ltd. |
Mammalian cells for producing adeno-associated viruses
|
CN110832072B
(zh)
|
2017-04-21 |
2023-11-07 |
真基因太科公司 |
用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
|
US11229692B2
(en)
|
2017-05-17 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
CN111163800A
(zh)
|
2017-09-15 |
2020-05-15 |
扬森疫苗与预防公司 |
用于安全诱导针对rsv的免疫的方法
|
JP7427584B2
(ja)
|
2017-10-13 |
2024-02-05 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
抗ウイルス導入ベクターigm応答を減弱化するための方法および組成物
|
CN111295449B
(zh)
|
2017-10-31 |
2023-12-05 |
扬森疫苗与预防公司 |
腺病毒载体及其用途
|
EA202091104A1
(ru)
|
2017-10-31 |
2020-08-12 |
Янссен Вэксинс Энд Превеншн Б.В. |
Аденовирус и пути его применения
|
MA50502A
(fr)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention Bv |
Adénovirus et utilisations associées
|
US11142551B2
(en)
|
2017-10-31 |
2021-10-12 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
CA3083183A1
(en)
|
2017-11-22 |
2019-05-31 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
EP3723771A4
(en)
|
2017-12-11 |
2022-04-06 |
Beth Israel Deaconess Medical Center, Inc. |
RECOMBINANT ADENOVIRUS AND THEIR USES
|
KR20200113226A
(ko)
|
2018-01-23 |
2020-10-06 |
얀센 백신스 앤드 프리벤션 비.브이. |
인플루엔자 바이러스 백신 및 이의 용도
|
WO2019173463A1
(en)
|
2018-03-06 |
2019-09-12 |
Intrexon Corporation |
Hepatitis b vaccines and uses of the same
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
CA3137448A1
(en)
|
2019-04-25 |
2020-10-29 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
MX2021013163A
(es)
|
2019-04-28 |
2022-02-21 |
Selecta Biosciences Inc |
Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral.
|
JP2022532723A
(ja)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与
|
JP2022532742A
(ja)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
|
EP3969046A1
(en)
|
2019-05-16 |
2022-03-23 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing a safe immune response against polio virus
|
US20200390718A1
(en)
|
2019-05-28 |
2020-12-17 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
EP4025247A1
(en)
|
2019-09-05 |
2022-07-13 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
JP2022551107A
(ja)
|
2019-10-03 |
2022-12-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベクターおよびその使用
|
AU2020361533A1
(en)
|
2019-10-08 |
2022-04-28 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
CA3161800A1
(en)
|
2019-11-18 |
2021-05-27 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
IL296103A
(en)
|
2020-03-05 |
2022-11-01 |
Neotx Therapeutics Ltd |
Methods and preparations for treating cancer with immune cells
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
BR112022021085A2
(pt)
|
2020-04-21 |
2022-12-27 |
Jjp Biologics Sp Z O O |
Anticorpos anti-cd89 humano humanizados e usos dos mesmos
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
US20230024133A1
(en)
|
2020-07-06 |
2023-01-26 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
TW202217002A
(zh)
|
2020-07-13 |
2022-05-01 |
法商傳斯堅公司 |
免疫抑制之治療
|
AU2021324670A1
(en)
|
2020-08-11 |
2023-02-02 |
Musculoskeletal Transplant Foundation |
Method for treating cardiac conditions with placenta-derived compositions
|
EP4340855A1
(en)
|
2021-08-13 |
2024-03-27 |
Triovance Holding LLC |
A skin substitute composition and methods of producing and using the same
|
WO2023064367A1
(en)
|
2021-10-12 |
2023-04-20 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
WO2023172624A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
EP4338727A1
(en)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus formulations
|